LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors
Status:
Unknown status
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the Maximum Tolerated Dose (MTD) of Panobinostat
(LBH589) when administered in combination with Carboplatin and Paclitaxel in patients with
advanced solid malignancies and to identify the Recommended Dose (RD) for a subsequent Phase
II study.